StockNews.AI
BLTE
StockNews.AI
155 days

Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website

1. Belite Bio filed annual report for year ended December 31, 2024. 2. Audited financial statements now available on their website. 3. Focus on therapies for degenerative retinal diseases with high unmet need. 4. Lead candidate Tinlarebant is in advanced clinical trials. 5. Company aims to address conditions like Stargardt disease and geographic atrophy.

3m saved
Insight
Article

FAQ

Why Bullish?

Positive indicator due to ongoing clinical trials and focus on unmet medical needs, similar to other biotech firms who saw stock price increases after positive trial results.

How important is it?

The disclosure of the annual report indicates transparency and progress in clinical trials which could improve investor confidence.

Why Long Term?

Long-term impact expected as clinical trial results could influence future valuations significantly, similar to other biotech stocks like Biogen.

Related Companies

BMYREGNBIIB
March 17, 2025 06:00 ET  | Source: Belite Bio, Inc SAN DIEGO, March 17, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a San Diego based clinical stage biopharmaceutical drug development company, today announced that its annual report on Form 20-F, containing audited consolidated financial statements for the year ended December 31, 2024, as filed with the Securities and Exchange Commission on March 17, 2025, is available through its website (https://www.belitebio.com). Shareholders may receive a hard copy of the annual report free of charge upon request. This press release is being issued pursuant to Nasdaq Listing Rule 5250(d)(1)(C). About Belite BioBelite Bio is a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical need, such as Stargardt disease type 1 (STGD1) and Geographic Atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite’s lead candidate, Tinlarebant, an oral therapy intended to reduce the accumulation of toxins in the eye, is currently being evaluated in a Phase 3 study (DRAGON) and a Phase 2/3 study (DRAGON II) in adolescent STGD1 subjects and a Phase 3 study (PHOENIX) in subjects with GA. For more information, follow us on Twitter, Instagram, LinkedIn, Facebook or visit us at www.belitebio.com. Media and Investor Relations Contact:Jennifer Wu ir@belitebio.com Julie Fallonbelite@argotpartners.com

Related News